Key Highlights

  • Third quarter adjusted revenues were USD 73.8 billion, and adjusted after-tax Earnings were USD 2.1 billion.
  • Adjusted EPS was USD 7.98, and the full year 2026 adjusted EPS outlook was raised to at least USD 30.60.
  • Total revenues were USD 73.683 billion for the quarter and USD 213.845 billion for the nine months, each up 6%.
  • Evernorth Pharmacy Services reported third quarter pretax adjusted earnings of USD 765 million, per management.

The Cigna Group (NYSE:CI) reported third quarter 2026 adjusted revenues of USD 73.8 billion and adjusted EPS of USD 7.98. Adjusted after-tax earnings were USD 2.1 billion.

President and Chief Executive Officer Brian Evanko said performance through the first nine months supported raising the full year 2026 adjusted EPS outlook to at least USD 30.60. He described the company's portfolio as positioned in the fastest growing areas of health care.

Revenue Drivers and Net Income

Pharmacy revenues were USD 58.982 billion, up 5%, primarily reflecting changes in claims composition within Pharmacy Benefit Services. Premiums increased 9% on premium rate increases within Cigna Healthcare. Fees and other revenues were USD 4.529 billion, up 3%, on growth in fee-based services within Evernorth Health Services. Net Investment income increased 23% on stronger returns from real estate investments and securities partnerships.

Shareholders' Net Income decreased 23% for the three months, which the company attributed to the absence of an after-tax gain on the sale of businesses recorded in the third quarter of 2025 and to lower net investment performance. For the nine months, shareholders' net income increased 1%.

For the nine months, total revenues were up 6% as well, while premiums decreased 5% because of the HCSC transaction, partly offset by premium rate increases.

Operating Updates

Management said Evernorth Pharmacy Services delivered pretax adjusted earnings of USD 765 million, and that the 2027 selling season shows high client retention and new Business wins in both Evernorth and Cigna Healthcare. Evernorth Wholesale began fulfilling orders to distribution centers, and the company launched its HealthSense offering with additional components to follow.

The company continues its Accelerate to One initiative, which targets run rate savings of USD 3 billion by 2030, and a Strategic Optimization Program announced in 2025.

Factors for 2027

Management outlined tailwinds and headwinds for 2027. The tailwinds include continued improvement in Stop Loss margins in Cigna Healthcare and the 2027 selling season results. The headwinds include a more limited pipeline of biosimilar and specialty generic launches within Evernorth Specialty and Care Services and the known exit from the ACA exchange business.

Prospective financial comments on the call include the potential impact of future share repurchases and anticipated 2026 dividends. The company said it provides further detail on its outlook on the fourth quarter call. Reported detail: Total revenues were USD 73.683 billion for the quarter and USD 213.845 billion for the nine months, each up 6%. Evernorth Pharmacy Services reported third quarter pretax adjusted earnings of USD 765 million, per management. Adjusted EPS was USD 7.98, and the full year 2026 adjusted EPS outlook was raised to at least USD 30.60.